home / stock / lixt / lixt news


LIXT News and Press, Lixte Biotechnology Holdings Inc. From 02/08/23

Stock Information

Company Name: Lixte Biotechnology Holdings Inc.
Stock Symbol: LIXT
Market: OTC
Website: lixte.com

Menu

LIXT LIXT Quote LIXT Short LIXT News LIXT Articles LIXT Message Board
Get LIXT Alerts

News, Short Squeeze, Breakout and More Instantly...

LIXT - Can Trading Penny Stocks Be a Full Time Job?

3 Ways to Make Income With Penny Stocks in 2023 Trading penny stocks has the potential to provide you with a full-time income, but it’s important to approach it with caution and knowledge. Penny stocks , which are defined as stocks that trade for less than $5 per share, can offer i...

LIXT - LIXTE BIOTECHNOLOGY HOLDINGS, INC. REPORTS THAT ITS LEAD CLINICAL COMPOUND, LB-100, CAN KILL CANCER CELLS THROUGH HYPER-STIMULATION OF CELL PROLIFERATION SIGNALS IN PRE-CLINICAL MODELS

-- THE STUDY ESTABLISH ES A NOVEL CONCEPT OF “TUMOR SUPPRESSIVE DRUG RESISTANCE” -- THE COMBINATION OF LB-100 WITH INHIBITORS OF CELLULAR STRESS RESPONSE MODULATORS WAS HIGHLY EFFECTIVE IN KILLING CANCER CELLS IN SEVERAL PRE-CLINICAL CANCER MODELS ...

LIXT - LIXTE Biotechnology Holdings to Present at Planet MicroCap Showcase: VIRTUAL 2022 Investor Conference

Presentation to be Broadcast Wednesday December 7 at 3:30 p.m. EST/12:30 p.m. PST PASADENA, CA / ACCESSWIRE / November 30, 2022 / LIXTE Biotechnology Holdings, Inc. (Nasdaq:LIXT) today announced it will be presenting at the Planet MicroCap Showcase: VIRTUAL 2022 investor conference Wednesday...

LIXT - LIXTE BIOTECHNOLOGY ANNOUNCES APPROVAL OF A PHASE 1B/2 RANDOMIZED TRIAL OF DOXORUBICIN +/-LB-100 IN ADVANCED SOFT TISSUE SARCOMAS TO BE CONDUCTED BY THE SPANISH SARCOMA GROUP

PASADENA, CA, Oct. 13, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), (“LIXTE” or the “Company”), a clinical-stage pharmaceutical company focused on developing and commercializing cancer therapies, announced that the Spanish A...

LIXT - LIXTE BIOTECHNOLOGY ANNOUNCES APPOINTMENT OF BAS VAN DER BAAN, INTERNATIONALLY RECOGNIZED BIOTECH BUSINESS DEVELOPMENT EXECUTIVE, TO ITS BOARD OF DIRECTORS

PASADENA, CA, June 21, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage pharmaceutical company focused on developing and commercializing cancer therapies, announced the appointment of Bas van der Baan to its Board of Directors. He will ser...

LIXT - LIXTE BIOTECHNOLOGY ANNOUNCES APPOINTMENT OF PROFESSOR RENÉ BERNARDS TO ITS BOARD OF DIRECTORS

Bernards is internationally recognized for his contributions to the development of effective anti-cancer drugs from their earliest stages through clinical use PASADENA, CA, June 15, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), ...

LIXT - Short Squeeze Stocks: RDBX, MDVL and 3 Others Experts Think Are Ready to Pop

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Short squeeze stocks are once again in focus today after the fifth straight week of market declines. As recession rumors swirl, let’s take a look at the short squeeze candidates receiving extra attention from investo...

LIXT - Trending Penny Stocks to Watch As the First Week of May Ends 

3 Trending Penny Stocks to Watch Right Now If you’re looking for trending penny stocks to buy, there are hundreds of options to choose from. But with so many stocks to pick from, it can be difficult to know where to start. One way to narrow down your choices is to look at the sto...

LIXT - Short Squeeze Stocks: HCDI, ZYME and 3 Others Experts Think Are Ready to Pop

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Short squeeze stocks are once again in focus this week as the economy prepares for this month’s planned interest rate hike. Indeed, as the bears are out and about, it’s no surprise to see short squeeze candida...

LIXT - Natus Medical, MedAvail top healthcare gainers; Nektar, TG Therapeutics lead losers' pack

Gainers: Natus Medical (NTUS) +30%. MedAvail (MDVL) +25%. IMARA (IMRA) +13%. Frequency Therapeutics (FREQ) +11%. Lyra Therapeutics (LYRA) +4%. Losers: Nektar Therapeutics (NKTR) -36%. TG Therapeutics (TGTX) -24%. Lixte Biotechnology (LIXT) -15%.&#x...

Previous 10 Next 10